According to an analysis of health records and other data (electronic health records and pharmacy dispensing data), overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's semaglutide. Within one year of starting treatment, 42.3% of those taking tirzepatide - the active ingredient in Mounjaro- had lost at least 15% of their weight, compared with 19.3% among patients taking semaglutide - the main ingredient in Wegovy and Ozempic.
After accounting for individual risk factors, patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%, compared to patients taking Ozempic, the report said.
Other findings were, after 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic; by 6 months, the difference had widened to 4.3%, and by 12 months, the Mounjaro group had lost an average of 7.2% more weight.
With regard to the side effects, rates of gastrointestinal adverse events were reported similar between groups.
The researchers note that Ozempic and Mounjaro are both intended for use by people with type 2 diabetes, but half of the study participants were using the drugs for weight loss only, which may have impacted the results. Novo Nordisk said, "The doses of semaglutide evaluated in this analysis have not been investigated for chronic weight management, and there are no head-to-head trials that have (been) reported which evaluate Wegovy and tirzepatide." Novo continued, "This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.”
A trial is underway comparing the weight loss formulations of the two injected medicines in patients overweight or obese, but without type 2 diabetes. The results of the study can help further provide a more reliable conclusion; however those results are not expected until 2025. In conclusion, based on the available data of analysis of health records, it seems like Mounjaro can lead to more weight loss, but this needs to be further evaluated in a trial.
Liked what you read?! Check out our other posts on weight loss at the links below:
Happy reading!
Reference:
Comments